Respiratory Disease Technology Company Indiso Reports Positive Preliminary Clinical Results With COPD Patients

Feb 11, 2016, 08:15 ET from DBH Investment Zrt.

BUDAPEST, Hungary, Feb. 11, 2016 /PRNewswire/ -- Indiso ltd, a medical technology company focusing on the unmet medical need of pulmonary and respiratory diseases announced today positive results in its clinical research program. The program focusing on COPD and asthma patients show improvements in respiratory functions and other clinical parameters.  

Upper and lower respiratory tract diseases and allergy create significant healthcare problems in the developed world and reached epidemic level. Increasing number of studies however show that there are complementary natural treatment options to the modern drug therapy in today's medical practice for treating these symptoms.

Dr. Katalin Vardi, principal investigator on the study, head of the Rehabilitation Department at the Torokbalint Pulmonology Clinic said: "Applying scientifically proven standards, we examined the effects of the Indiso Speleo Therapy on 100 COPD and asthma patients. This therapy shows very encouraging results especially for patients with serious lower respiratory diseases. Patients showed encouraging improvements in 6 minutes walking distance and apneal time, while their respiratory parameters also improved significantly."

Dr. Istvan Laki, head of the Pediatric Department at the Torokbalint Pulmonology Clinic added: "For respiratory disease patients the Indiso Speleo Therapy resulted in improved respiratory functions, in many cases by 10%, while the symptom's scoring systems improved by 30%.  The therapy effectively dissolves the respiratory mucus and can get similar results as standard drug therapy but with no side effects. All our patients reported improvement in their conditions and in their quality of life as well. We look forward to continuing this very promising study and expanding it to a larger patient population."

Dr. Laszlo Urge, Board member at DBH Investment, the venture capital investor in Indiso added:  "We are very encouraged by these results and are proud that this technology can have such a significant positive impact on patients suffering from these respiratory symptoms. These results may also have significant economic impact on healthcare systems, since there are calculations that just in the EU spending an additional €5-8 Bln could save €55-151 billion on allergy and respiratory problems." 

About Indiso

Indiso is a healthtech company focusing on the unmet medical need of respiratory and pulmonary diseases to eliminate the syndromes and improve patient's life. The company has a proprietary technology portfolio.  Doctors recommend the Indiso Speleo Therapy for different pulmonary diseases.

Logo - http://photos.prnewswire.com/prnh/20160210/331945LOGO

SOURCE DBH Investment Zrt.



RELATED LINKS

http://www.indiso.eu/english/564